Viral Vector Service Market Report 2026

Viral Vector Service Market Overview

• Viral Vector Service market size has reached to $2.53 billion in 2025 • Expected to grow to $7.41 billion in 2030 at a compound annual growth rate (CAGR) of 23.9% • Growth Driver: Growing Prevalence Of Infectious Diseases Fueling The Growth Of The Market Due To Rising Incidence And Need For Efficient Vaccine And Therapeutic Development • Market Trend: Advanced Platforms Enable High-Titer Stable Producer Cell Lines • North America was the largest region in 2025.

What Is Covered Under Viral Vector Service Market?

Viral vector service refers to the process of designing, producing, and validating viral vectors used for gene delivery in research and therapeutic applications. These services enable the safe and efficient transfer of genetic material into target cells for the development of advanced biologics and gene therapies. They ensure high-quality vector production through standardized protocols and regulatory compliance. The main service types of viral vector services are process development, manufacturing, quality control, and others. Process development is the systematic design, optimization, and scaling of a manufacturing or production process to ensure it is efficient, reproducible, and meets quality standards. These services are applied across various vector types, including adenoviral vectors, lentiviral vectors, adeno-associated viral (AAV) vectors, retroviral vectors, and others. It finds applications in gene therapy, vaccinology, oncology, and others, serving end-users such as pharmaceutical and biotechnology companies, research institutes, and others.

What Is The Viral Vector Service Market Growth Forecast?

The viral vector service market size is expected to see exponential growth in the next few years. It will grow to $7.41 billion in 2030 at a compound annual growth rate (CAGR) of 23.9%. The growth in the forecast period can be attributed to increasing commercialization of gene-based therapies, rising demand for customized vector solutions, expansion of contract service partnerships, growing regulatory requirements for viral vectors, increasing investment in advanced vector technologies. Major trends in the forecast period include increasing demand for end-to-end viral vector services, rising adoption of integrated development and manufacturing models, growing focus on quality-controlled vector production, expansion of custom vector design capabilities, enhanced emphasis on regulatory compliance services.

What Is The Driver Of The Viral Vector Service Market?

The growing prevalence of infectious diseases is expected to propel the growth of the viral vector services market going forward. Infectious diseases are illnesses caused by pathogenic microorganisms, such as bacteria, viruses, fungi, or parasites, that can be transmitted directly or indirectly from one individual to another. The rate of infectious disease incidence is rising due to increased travel, which facilitates the rapid spread of pathogens across borders. Viral vector services support infectious-disease management by providing reliable platforms for developing vaccines and gene-based therapeutics. They enable efficient delivery of genetic material to target cells, accelerating the creation of effective treatments and improving public health response. For instance, in February 2024, according to the UK Health Security Agency, a UK-based government agency, tuberculosis (a contagious bacterial infection that primarily affects the lungs) cases in England rose to 4,850 in 2023, an increase of 10.7% from 4,380 cases in 2022. Therefore, the growing prevalence of infectious diseases is driving the growth of the viral vector services industry.

Key Players In The Global Viral Vector Service Market

Major companies operating in the viral vector service market are Merck KGaA, Thermo Fisher Scientific Inc., Lonza Group AG, FUJIFILM Diosynth Biotechnologies, Danaher Corporation, Sartorius AG, Charles River Laboratories Inc., Takara Bio Inc., Oxford Biomedica plc, ProBioGen AG, NorthX Biologics Ltd., PackGene Biotech Ltd., Ascend Advanced Therapies Ltd., VectorBuilder Inc., ViroCell Biologics Ltd., Genezen Ltd., Scorpius BioManufacturing Ltd., VGXI Inc., Creative Biogene Ltd., ReiThera Ltd., Tailored Genes Ltd., CoJourney Ltd., InnovaVector Ltd.

Global Viral Vector Service Market Trends and Insights

Major companies operating in the viral vector service market are focusing on innovation in lentiviral vector design and manufacturing, such as fourth-generation vector systems, to enhance payload capacity, potency, and safety while streamlining the development of complex gene therapies. Fourth-generation vector systems refer to advanced lentiviral delivery technologies engineered with improved safety profiles, optimized gene packaging capabilities, and modular components that support scalable plug-and-play manufacturing for cell and gene therapies. For instance, in May 2023, Oxford Biomedica plc, a UK-based viral vector contract development and manufacturing organization (CDMO), launched the TetraVecta system. The system improves vector quality, potency, and packaging efficiency while incorporating advanced safety features. It enables the creation of high-titer, stable producer cell lines, supporting scalable in vivo gene therapy development. TetraVecta streamlines the manufacturing process, reducing production timelines and enhancing overall efficiency for gene therapy programs.

What Are Latest Mergers And Acquisitions In The Viral Vector Service Market?

In October 2025, Oxford Biomedica plc, a UK-based cell and gene therapy contract development and manufacturing organization, acquired RTP Operating LLC for $4.5 million (£3.4 million). Through this acquisition, Oxford Biomedica (OXB) expands its United States (US) commercial-scale viral vector manufacturing capabilities, enhancing its end-to-end contract development and manufacturing organization (CDMO) services, increasing good manufacturing practice (GMP) capacity, and supporting clinical and commercial gene therapy programs for existing and new clients. RTP Operating LLC is a US-based biopharmaceutical company that provides a commercial-scale viral vector manufacturing facility.

What Defines the Viral Vector Service Market?

The viral vector service market includes revenues earned by entities through vector design, process development, analytical testing, scale-up production, quality control, regulatory support, purification, and fill and finish. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Viral Vector Service Market Report 2026?

The viral vector service market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the viral vector service industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.